Other in-human trials are currently underway, including a phase I trial (NCT05680922) studying LB2102 in ES-SCLC, a phase I trial studying SNC-115 in recurrent/refractory SCLC and neuroendocrine carcinoma (NCT06384482), and a phase I trial investigating BHP01, a DLL3 targeted α-PD-L1/4-1BB CAR-T (NCT06348797). This evidence concerns the gene CD274 and small cell lung carcinoma.